Response to:Comorbidities in a Mexican Mestizo cohort with established rheumatoid arthritis
MaximeDougados, Professor,
April 13, 2016
Dear Editor,
On behalf of the investigators of the COMORA study, we would like to
congratulate for the study you have conducted in Mexican mestizo patients.
The results observed are totally in accordance with the results observed
in the COMORA study that is: 1/ a relevant percentage of rheumatoid
arthritis patients with comorbidities and 2/ a huge inter-country
variability.
We would like to echo our Mexican colleagues that, in accordance to
the EULAR recommendations, these studies emphasize the need of a yearly
evaluation of such comorbidities. Such studies (the COMORA one and the one
conducted in Mexico) could facilitate the standardization of the way to
collect such comorbidities in patients with chronic inflammatory
disorders.
Dear Editor,
On behalf of the investigators of the COMORA study, we would like to congratulate for the study you have conducted in Mexican mestizo patients. The results observed are totally in accordance with the results observed in the COMORA study that is: 1/ a relevant percentage of rheumatoid arthritis patients with comorbidities and 2/ a huge inter-country variability.
We would like to echo our Mexican colleagues that, in accordance to the EULAR recommendations, these studies emphasize the need of a yearly evaluation of such comorbidities. Such studies (the COMORA one and the one conducted in Mexico) could facilitate the standardization of the way to collect such comorbidities in patients with chronic inflammatory disorders.
Conflict of Interest:
None declared